Press releases

18 Oct 2023

BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

17 Oct 2023

UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for the treatment of adults with generalized myasthenia gravis

13 Oct 2023

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

12 Oct 2023

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

9 Oct 2023

UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023

25 Sep 2023

UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan

Press releases

Press releases

Search Press releases

BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for the treatment of adults with generalized myasthenia gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023

UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan

Choose a Country

Hypothesize That! Discover our new science podcast, where science meets conjecture and curiosity

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

At UCB, we imagine an HS-free world. And we’re taking steps to make it a reality. Download our...

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Integrated Annual Report 2024 - Click here to access the report

UCBCares® - Discover what UCBCares® is about and the services they offer

Driving innovation forward: UCB unveils new R&D facility

UCB Announces Major U.S. Investment to Expand Biologics Manufacturing Capacity

Global data show real-world effectiveness of romosozumab for patients at high fracture risk

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth

UCB completes sale of established brands and updates 2024 financial guidance

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

BIMZELX[®] Approved by the U.S. FDA for the Treatment of Adults with Moderate to Severe Plaque Psoriasis

UCB announces U.S. FDA approval of ZILBRYSQ[®] (zilucoplan) for the treatment of adults with generalized myasthenia gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psoriasis and Psoriatic Arthritis at EADV 2023

UCB announces approval of RYSTIGGO[®] (rozanolixizumab) and ZILBRYSQ[®] (zilucoplan) for the treatment of adult patients with generalized myasthenia gravis in Japan

Choose a Country